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Video-assisted Thoracoscopic surgery
(VATS) lobectomy for lung cancer does
not induce a procoagulant state
Thomas Decker Christensen1,2* , Henrik Vad1,2, Søren Pedersen3,4, Peter B. Licht5, Mads Nybo6, Kåre Hornbech7,
Nora Elisabeth Zois8 and Anne-Mette Hvas9,10
Abstract
Background: Changes in the coagulation system in patients undergoing surgery for lung cancer have been sparsely
investigated and the impact of the surgical trauma on the coagulation system is largely unknown in these patients. An
increased knowledge could potentially improve the thromboprophylaxis regimes. The aim of this study was to assess
the coagulation profile evoked in patients undergoing curative surgery by Video-Assisted Thoracoscopic Surgery (VATS)
lobectomy for primary lung cancer.
Methods: Thirty-one patients diagnosed with primary lung cancer undergoing VATS lobectomy were prospectively
included. The coagulation profile was assessed preoperatively and in the first two days postoperatively using a wide
range of standard coagulation tests, dynamic whole blood coagulation measured by rotational thromboelastometry
(ROTEM®) and thrombin generation evaluated by calibrated automated thrombography. Patients did not receive
thromboprophylactic treatment. Data was analyzed using repeated measures one-way ANOVA.
Results: The standard coagulation parameters displayed only subtle changes after surgery and the ROTEM® and
thrombin generation results remained largely unchanged.
Conclusions: Patients undergoing VATS lobectomy are normocoagulable in the preoperative state and a VATS
lobectomy does not significantly influence the coagulation.
Trial registration: The trial is registered at ClinicalTrials.gov (Identifier: NCT01741506) and at EudraCTno. 2012–002409-23.
Registered December 2012.
Keywords: Venous thrombosis, Blood coagulation test, Blood coagulation, Lung neoplasm, Thoracic surgery, Video assisted
Background
Cancer patients have an increased risk of venous thrombo-
embolic events (VTE) consisting of deep venous throm-
bosis (DVT) or pulmonary embolism (PE) [1]. The risk
factors for VTE are either patient-related (e.g. age, obesity),
cancer-related (e.g. histopathologic type of cancer and ad-
vanced stage), treatment-related (e.g. surgical procedure,
chemotherapy), or a combination of these factors [2, 3].
Patients having potentially curative operations for lung
cancer differ substantially from other lung cancer patients,
since they suffer predominantly from early-stage disease.
Accordingly, presence of a procoagulant imbalance is not
as likely as it is in patients with more advanced disease
[3, 4], but has not been investigated.
The influence on the coagulation system in patients
undergoing thoracic (non-cardiac) surgery has only been
sparsely investigated. Specifically, serial investigations of
the coagulation system in the post-operative phase are
lacking. Additional knowledge is warranted, since patients
undergoing surgery for lung cancer still have an increased
long-term risk of VTE [1–3].
New knowledge could potentially change the thrombo-
prophylaxis regimen, e.g. regarding type of medication
(Non-vitamin K antagonist oral anticoagulant (NOAC)
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versus Low-Molecular-Weight Heparin (LMWH)), dose,
and timing (e.g. start-up after discharge from hospital and
given on a long-term basis).
Papageorgiou et al. [5] found patients with lung adeno-
carcinoma undergoing lobectomy to be hypercoagulable
pre- and postoperatively, whereas Swiniarska et al. [6]
reported that surgery resulted in an activation of the
coagulation system, however significantly more profound
in pneumonectomies compared to lobectomies. In a
porcine model Trabjerg et al. [7] showed that there was
no significant activation of the coagulation system dur-
ing lung surgery. Thus, results of the published studies
are conflicting and inconclusive. In order to estimate
the activation of the coagulation system, advanced and
validated methods should be applied. Using rotational
thromboelastometry (ROTEM®), thrombin generation
and standard coagulation parameters, a quantification
of the coagulation system can be performed [8, 9].
We hypothesized that patients with primary lung cancer
were hypercoagulable before surgery, and that the coagula-
tion profile changes after surgery in terms of an activation
of the coagulation system. The aim of this study was to as-
sess the coagulation profile evoked in patients undergoing
curative surgery by Video-Assisted Thoracoscopic Surgery
(VATS) lobectomy for primary lung cancer.
Methods
Patient population
The present study is a sub-study to a larger randomized
study already published, and the design is thus reported
elsewhere [10].
Briefly, approximately 750 patients from a catchment area
of 4,500,000 inhabitants are annually referred to Aarhus
University Hospital, Rigshospitalet (University Hospital of
Copenhagen) or Odense University Hospital, Denmark, to
undergo surgery for primary lung cancer. From March
2013 to April 2015, patients who underwent lobectomy at
one of these three sites were screened for eligibility.
Inclusion criteria were as follows: (1) Diagnosed with
primary lung cancer with a preoperative stage IA-IB; (2)
Surgery with expected lobectomy or bi-lobectomy using
VATS; (3) Willingness to participate and ability to give
informed oral and written consent; (4) No thrombopro-
phylaxis received before or after surgery; and (5) > 18 years
of age. Exclusion criteria were: (1) Thromboembolic event
(either arterial or venous) within the past three months;
(2) Pregnant or lactating; (3) Treatment with vitamin K-
antagonist or a NOAC; or (4) Treatment with a platelet
inhibitor if this was not paused for a minimum of 5 days
(aspirin, clopidogrel or ticagrelor) or 7 days (prasugrel).
No patients had received neoadjuvant chemo- and/or
radiation therapy prior to surgery.
The patients were included after oral and written con-
sent. The study protocol complied with the Helsinki II
declaration and was approved by the local scientific eth-
ical committee (File number: 1–10–72-364-12) and The
Danish Data Protection Agency. The study was conducted
according to Good Clinical Practice (GCP) standards and
was monitored and approved by the GCP-unit, Aarhus
University Hospital, Aarhus, Denmark. The trial is regis-
tered at ClinicalTrials.gov (Identifier: NCT01741506) and
at EudraCTno. 2012–002409-23.
Included patients were randomized to treatment with
either LMWH or no intervention. In the present study,
only the subpopulation of patients receiving no interven-
tion was included.
Intervention
All operations were performed in general anaesthesia with
propofol and fentanyl. The VATS approach used has previ-
ously been described in details [11]. Briefly, an anterior ap-
proach with one incision and two port assist incisions were
performed, and one chest tube was placed. All patients
were intubated with a Carlens double-lumen tube, extu-
bated immediately after surgery and stayed approximately
12 h in the high dependency unit and then transferred back
to the ward. The patients were mobilized within hours of
finishing the operation and no mechanical thromboprophy-
laxis was provided.
Observation period and blood analyses
Due to logistics it was not possible to perform the co-
agulation analyses during weekends; accordingly, only
patients operated on Mondays, Tuesdays and Wednes-
days were included. Accordingly, the inclusion period
was somewhat elongated.
Blood samples were obtained and analyzed at the fol-
lowing three time-points: 1) Preoperatively; the day before
surgery; 2) Postoperatively 0800 AM at day 1; and 3) Post-
operatively 0800 AM at day 2.
The first 2 ml of blood was discarded before drawing
blood into tubes containing sodium citrate for ROTEM®
analyses, thrombin generation and standard coagulation
analyses including: Activated partial thromboplastin time
(APTT), International Normalized Ratio (INR), fibrinogen
(functional), fibrin d-dimer, platelet count and coagulation
factor VIII:Clot. Blood for ROTEM® analyses were left at
room temperature for 30 min before processing, whereas
the remaining analyses were done either immediately as
routine analyses or blood samples were centrifuged at
2800 g for 25 min and plasma was stored in aliquots
at −80 °C until analysis.
Regarding ROTEM® (Tem International GmbH, Munich,
Germany), three standard assays were performed: INTEM,
EXTEM, and FIBTEM. We obtained the dynamic parame-
ters of clot initiation (clotting time: CT, seconds (s)) and clot
propagation (maximum velocity of clot formation: MaxVel,
mm × 100/s, time to maximum velocity: tMaxVel, s). Whole
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blood clot strength was assessed by maximum clot firmness
(MCF, mm × 100).
Thrombin generation was evaluated by calibrated
automated thrombograms (CAT; Thrombinoscope BV,
Maastricht, the Netherlands) using platelet-poor plasma.
The following parameters were analyzed: Lag-time until
initial thrombin generation (minutes), maximum concen-
tration of thrombin (peak, nM), time to peak (ttpeak,
minutes), and the endogenous thrombin potential (ETP,
nM x minutes).
The normal range for the ROTEM® was calculated
based on data obtained from 73 healthy individuals previ-
ously published [12], and the normal range for thrombin
generation were obtained from 90 individuals published
by Vibede et al. [13].
APTT (Platelin LS, Organon, Munich, Germany), INR
(Owren’s PT-reagent, MediRox), fibrinogen (Clauss method,
Siemens Dade reagent) were analyzed employing the
CS2100i (Sysmex, Kobe, Japan) Coagulation factor
VIII:Clot (factor VIII:Clot) was analyzed by ACL-TOP
(Instrumental Laboratory, Bedford, MA, USA).
Preoperatively, the following baseline analyses were
performed: haemoglobin, leukocytes, platelet count, cre-
atinine, INR and C-reactive protein (CRP).
Preoperative (baseline) data in terms of clinical character-
istics was collected systematically from medical records.
Furthermore, intra- and postoperative data (operating time,
bleeding during surgery, transfusion, total drain loss, VTE
and adverse events, length of stay and pathological staging)
were registered prospectively in a case report form.
Statistical analyses, endpoints and sample size
Baseline and postoperative characteristics were tested for
normal distribution and hence presented as either mean
and standard deviation (SD) or median and 95% confidence
interval (CI) or as minimum to maximum values.
The results of the coagulation analyses were tested using
repeated measures one-way ANOVA, sphericity was not as-
sumed and alpha was set to 0.05. All three measurements
(preoperatively, 1. postoperative day and 2. postoperative
day) were needed, otherwise the patient’s measurements for
that specific parameter was excluded.
Microsoft® Excel® for Mac 2011 (Microsoft®, Seattle, USA)
and GraphPad Prism 6 for Mac (GraphPad Software, Inc.,
CA, USA) were used for the statistical analyses.
The study was explorative in nature, and a sample size
calculation was therefore not performed prior to the in-
clusion of patients.
Results
Figure 1 displays the trial flowchart. A total of 81 VATS-
patients were randomized; 40 patients to the LMWH
arm and 41 patients to the no intervention arm (a trial
flowchart is displayed in Fig. 1). Patients randomized to
the LMWH arm were excluded in the present study, and
these results are published elsewhere [10].
In the no intervention arm, 10 patients were excluded
(Fig. 1), and a total of 31 patients were therefore included
in the present study. Among these, three patients had
been given NSAID, and additionally three patients were
converted to an open procedure. Three patients were
operated at Odense University Hospital, three patients at
Rigshospitalet (University Hospital of Copenhagen), and
25 at Aarhus University Hospital.
None of the included patients had a previously event
of VTE.
Six patients (19%) received aspirin before being admit-
ted to surgery, but all patients paused their aspirin at least
5 days prior to surgery.
Fig. 1 Trial flowchart for patients planned for Video-Assisted Thoracoscopic Surgery (VATS) lobectomy for primary lung cancer. The number of
patients assessed for eligibility is not shown. Abbreviations: n/N: numbers; ASA: Acetylsalicylic acid (aspirin); LMWH: Low-Molecular-Weight
Heparin; NSAID: Non Steroid Anti Inflammatory Drug
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Table 1 shows preoperative characteristics, while the
intra- and postoperative data are displayed in Table 2.
Three patients received transfusion during surgery; one
patient received red blood cells, platelets and fresh fro-
zen plasma; one patient received red blood cells and
platelets and one patient received merely red blood cells.
The results of the ANOVA analyses regarding the stand-
ard coagulation blood tests, ROTEM® results and thrombin
generation are displayed graphically in Figs. 2, 3, and 4.
The findings illustrated in Figs. 2, 3, 4 shows a statisti-
cally significant change (p-values are displayed in Figs. 2,
3, and 4) over time from pre- to the postoperatively state
for a total of nine parameters. An increased fibrinogen,
fibrin d-dimer, factor VIII:Clot and FIBTEM MCF was
found reflecting a hypercoagulable state The following
changes reflected a hypocoagulable state: an increase in
INR, and a decrease in platelet count, INTEM tMaxVel
and time to peak.
Discussion
The main findings of the present study were that patients
undergoing VATS lobectomy are normocoagulable in the
preoperative state and that VATS lobectomy does not
have significantly impact on coagulation. Only very few
variables were found statistically significantly affected on
the postoperative day 2. However, none of these changes
was of clinical relevance.
This is a sub-study of a larger study, where patients
undergoing curative surgery for primary lung cancer with
the use of VATS were randomized to either LMWH or no
Table 1 Baseline data (preoperative) of the study population
prior to Video-Assisted Thoracoscopic Surgery (VATS) lobectomy
for lung cancer, n = 31
Variables Values
Age (years) 67 (10)
Sex (female/male), n 20/11
Non smoker/ex-smoker/ active smoker, n 1/19/11
Pack years of smoking 30 (20)
FEV 1 (% of expected) 91 (20)
DLCO (% of expected) 69 (17)
BMI 25 (4)
Co-morbiditya, n (%):
Diabetes mellitus 2 (7)
Hypertension 12 (39)
Hyperlipidemia 10 (31)
Cardiac and/or vascular disease 4 (13)
Previous malignant disease 8 (26)
ASA prescribed, n (%) 6 (19)
Laboratory analyses (reference interval):
B - Haemoglobin (women: 7.3–9.5 mmol/L; men:
8.3–10.5 mmol/L)
8.5 (0.7)
B - Leukocytes (3.5–10.0 × 109/L) 7.5 (2.0)
P - Creatinine (women: 45–90 μmol/L; men:
60–105 μmol/L)
72 (18)
B - Platelet count (145–400 × 109/L) 287 (85)
P - C-reactive protein (8 mg/L) 4 (4)
P - INR (< 1.2) 1.0 (0.1)
P - APTT (25–38 s) 30 (4)
Abbreviations: B Blood, N/n Numbers, P Plasma, APTT Activated partial
thromboplastin time, ASA Acetylsalicylic acid (aspirin), BMI Body Mass Index,
DLCO Diffusion Capacity of the Lung for Carbon Monoxide, FEV1 Forced
Expiratory Volume in one second, INR International Normalized Ratio
All values are provided either as mean and (standard deviation) or numbers
and (percentage)
aDefined as the patient being in medical treatment for the disease
Table 2 Peri- and postoperative data of the study population
following Video-Assisted Thoracoscopic Surgery (VATS) lobectomy
for lung cancer, n = 31
Variables (n) Values
Type of lobectomy (n)
Right Upper Lobe 10
Right Middle Lobe 1
Right Lower Lobe 10
Left Upper Lobe 7
Left Lower Lobe 3
Operating time (h:m) 2:31 (0:47)
Bleeding/drainage during surgery (ml) 100 (0–2000)
Use of inotropes (patients, n)a 15
Re-operated 1
Total amount of fluid in the chest drain (ml) 850 (50–6135)
Complicationsb 5c
VTE events 0
Death 0
Total length of stay (days) 5.5 (3.2–20.0)
Type of cancer
Adenocarcinoma 23
Squamous cell carcinoma 4
Carcinoid (all types) 1
Othersd 3
Pathological staging
Stage IA + B 27
Stage IIA + B 4
Microscopically free resection margins (R0) 31
Abbreviations: H Hours, N/n Numbers, M Minutes, ml milliliter, VTE Venous
Thromboembolic Events
Operating time was normal distributed and is shown as mean and (standard
deviation) in parenthesis, but the other data were not normally distributed
and are accordingly displayed as median and (minimum to maximum)
aPredominantly small doses of methaoxidrin or efedrin
bIncludes myocardial infarction, apoplexia cerebri and atrial fibrillation
cApoplexia cerebri (n = 2) and atrial fibrillation (n = 3)
dIncludes small cell carcinoma, neuroendocrine and sarcomatoid tumor
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Fig. 2 Conventional coagulation tests among 31 patients undergoing Video-Assisted Thoracoscopic Surgery (VATS) lobectomy for lung cancer.
The p – values for the result of the ANOVA test are displayed. Values are shown as mean and standard deviation (SD), and dotted lines display
the normal range (mean +/− 1.97 * SD) for healthy subjects established by the Department of Clinical Biochemistry, Aarhus University Hospital,
Denmark. Abbreviations: APTT = Activated partial thromboplastin time INR = International Normalized Ratio
Fig. 3 Rotem® results among 31 patients undergoing Video-Assisted Thoracoscopic Surgery (VATS) lobectomy for lung cancer. The p – values for
the result of the ANOVA test are displayed. Values are shown as mean and standard deviation (SD), and dotted lines display the normal range
(mean +/− 1.97 * SD) [12]. Abbreviations: CT = Clotting Time MaxVel = Maximum Velocity tMaxVel = Time to Maximum Velocity MCF =Maximum
Clot Firmness
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thromboprophylaxis [10]. In that study, we found that the
use of LMWH administered once daily as thrombopro-
phylaxis did not alter the coagulation profile per se.
In order to investigate the temporal changes in the co-
agulation profiles of surgical patients, we included a group
of lung cancer patients undergoing surgery receiving no
thromboprophylaxis. Accordingly, we were able to follow
the natural course of the coagulation system pre- and
postoperatively.
The previously published studies within this area have
some major limitations. The study by Trabjerg et al. [7]
employed a porcine non-cancerous model, which does not
necessarily reflect changes occurring in human coagulation
[14]. The studies by Papageorgiou et al. [5] and Swiniarska
et al. [6] had the drawback of using mainly standard blood
analysis and determination of tissue factor concentration
instead of global analysis as e.g. ROTEM® and thrombin
generation. In contrast, the parameters used in the present
study reflected the overall impact on the coagulation
system [8, 9]. Moreover, it has even been advocated that
thromboelastometry can be able to predict the risk of
VTE after surgery [15].
The changes in the parameters fibrin d-dimer, factor
VIII:Clot and FIBTEM MCF reflected a subtle hyperco-
agulability, while a small degree of hypocoagulability was
displayed in the parameters INR, platelet count, INTEM,
tMaxVel and time to peak. The absolute changes in the
coagulation parameters were however small indicating
that these changes are probably not of major clinical
relevance.
Our patients were operated by a minimal invasive
approach and VATS lobectomies are supposed to in-
duce a reduced surgical stress compared to an open
procedure [11], which probably adds to the low activa-
tion of and impact on the coagulation system. Accordingly,
one can question whether this patient group benefits from
thromboprophylaxis provided in the period around surgery.
Further studies are obviously needed including clinical
endpoints.
We chose not to include analyses of coagulation pa-
rameters during surgery, since they are influenced by
several intra-operative factors such as anesthesia, surgi-
cal stress and bleeding, which introduce considerable
variability. Furthermore, our aim was to investigate the
changes in the coagulation profile evoked by surgery.
Of note, the present study was merely a descriptive
study, since we did not perform any interventions.
Our study has some limitations because we used sur-
rogate and not clinical endpoints in terms of VTE and
bleeding events. However, the use of clinical endpoints
would imply inclusion of a very large group of patients,
because these events are relatively rare. Additionally, we
only included blood samples up to two days after surgery
and in a limited number of patients (n = 31).
The relatively low number of patients limits the con-
clusions that can be drawn from this study.
Nevertheless, we find that this fully reflects the entire
intra- and postoperative period, and blood samples drawn
e.g. on postoperative day 14 and day 30 would probably not
have altered our conclusion, because the investigated pa-
rameters were un-altered following surgery. A larger group
of patients would of course have solidified our conclusions.
We found a relatively marked variability between the
individual patients at different time points for some of
the ROTEM® parameters and thrombin generation vari-
ables. Even among healthy individuals the measurements
in question have a relatively large variability and this fact
should be taken into consideration when interpreting
the results.
Besides coagulation, it would be relevant to investigate
inflammatory markers in order to elucidate the cross-
talk between the inflammatory and the coagulation sys-
tems. However, this was beyond the scope of this study.
Changes in coagulation are predominantly reported in
adenocarcinomas, but is likely to also exist in other histo-
pathological types [6]. However, we could have obtained
more clearcut results, if we had included merely one type
of cancers i.e. adenocarcinomas. Yet, the majority of cases
Fig. 4 Thrombin generation among 31 patients undergoing Video-Assisted Thoracoscopic Surgery (VATS) lobectomy for lung cancer. The p – values
for the result of the ANOVA test are displayed. Values are shown as mean and standard deviation (SD), and dotted lines display the normal range
(mean +/− 1.97 * SD) [13]
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included herein were adenocarcinomas (23 out of 31
patients corresponding to 74%).
We had a relatively high dropout rate due to the com-
plex set-up with the blood sampling and analyses, poten-
tial interaction with medication (e.g. aspirin and NSAID)
and accordingly a slow inclusion rate of patients. How-
ever, this is not assumed to have interfered with either
the internal or external validity of our study.
Since all patients paused their aspirin at least 5 days prior
to surgery, it is thus unlikely that aspirin administration
had any impact on the conclusions drawn from this study.
The surgical procedure and technique remained the same
over the entire study period. Three patients were converted
to an open procedure, mainly due to bleeding, and three
patients received NSAID postoperatively. We decided to
include these patients in our analysis, and the inclusion did
not affect the overall conclusions drawn from the study.
In order to perform a repeated measures ANOVA ana-
lyses, no missing observations were tolerated. Hence, a
smaller number of patients were excluded from the stat-
istical analysis of the respective parameters resulting in a
resultant sample size of 26–29.
Conclusions
Patients undergoing VATS lobectomy are normocoagulable
in the preoperative state and a VATS lobectomy does not
significantly influence the coagulation.
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